Barthel P Schneider

Learn More
BACKGROUND Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension. METHODS A genome-wide association study (GWAS) was performed in the phase III bevacizumab-based adjuvant breast cancer trial, ECOG-5103, to evaluate for an association between(More)
  • Watanabe M, Zipes Dp, +20 authors Schomig A
  • 2009
Oscillations of diastolic interval and refractory period following premature and postmature stimuli in canine cardiac Purkinje fibers. Reduction of prognostic power of ventricular late potentials in post­myocardial infarction patients in the reperfusion era. Watanabe MA. Heart rate turbulence slope reduction in imminent ventricular tachyarrhythmia and its(More)
  • 1